Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bcl-2 inhibitor plus blinatumomab induction vs pediatric-inspired chemotherapy in adult Ph-negative ALL
ChiCTR2500111430Phase 2Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Oct 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: The rate of minimal residual disease negativity (flow cytometry). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2500111430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111430.